Back to search

Article

Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma

2025-07-10

Abstract excerpt

<h4>Background</h4> Despite improved outcomes with atezolizumab plus bevacizumab (A+B) in hepatocellular carcinoma (HCC), primary refractoriness (PRef), characterised by early progression or short-lived disease stabilisation following treatment, remains a significant and poorly understood clinical challenge. <h4>Methods</h4> We analysed 1296 patients with HCC and Child-Pugh A liver cirrhosis treated with frontli...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
dddb7a32-ce42-59a8-b174-57e9f5b09440
DOI
10.1101/2025.07.08.663653
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinomaDOI 10.1101/2025.07.08.663653
Differential T-cell and monocyte responses in hepatocellular carcinoma treated with regorafenib plus nivolumab: an integrated clinical and biomarker analysis of the phase 2 RENOBATE trialSemantic proximity
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular CarcinomaSemantic proximity
Distinct Single-cell Immune Ecosystems Distinguish True and <i>De Novo</i> HBV-related Hepatocellular Carcinoma RecurrencesSemantic proximity
Identifying functional drivers of Hepatoblastoma outcomes via agent-based modeling and transcriptomicsSemantic proximity
Clinical significance of circulating biomarkers of immune checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinomaSemantic proximity
Distinct single-cell immune ecosystems distinguish true and de novo HBV-related hepatocellular carcinoma recurrencesSemantic proximity
Precision targeting of β-catenin induces tumor reprogramming and immunity in hepatocellular cancersSemantic proximity
Molecular signatures of chronic antibody-mediated rejection in human liver transplantsSemantic proximity
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain.Semantic proximity
Locally constrained immune-interaction fronts at tumor–immune interfaces are associated with immunotherapy response in hepatocellular carcinomaSemantic proximity
Locally constrained immune-interaction fronts at tumor–immune interfaces are associated with immunotherapy response in hepatocellular carcinomaSemantic proximity
Clinical outcomes of chimeric antigen receptor T cell therapy in 21 patients with Relapse/Refractory Ileocecal B cell lymphomaSemantic proximity
Select a neighboring publication to make it the new centre.